Today's Top Performers In Health Care

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,367 as of Wednesday, March 5, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,229 issues advancing vs. 1,681 declining with 174 unchanged.

The Health Care sector currently sits up 0.1% versus the S&P 500, which is unchanged. Top gainers within the sector include Boston Scientific Corporation ( BSX), up 1.1%, Express Scripts ( ESRX), up 0.9%, Regeneron Pharmaceuticals ( REGN), up 0.8%, Celgene Corporation ( CELG), up 0.7% and AbbVie ( ABBV), up 0.7%. On the negative front, top decliners within the sector include XOMA ( XOMA), down 26.1%, Mylan ( MYL), down 1.9%, Biomarin Pharmaceutical ( BMRN), down 1.8%, Shire ( SHPG), down 1.4% and Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.3%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Arrowhead Research Corporation ( ARWR) is one of the companies pushing the Health Care sector higher today. As of noon trading, Arrowhead Research Corporation is up $5.03 (23.8%) to $26.17 on heavy volume. Thus far, 4.8 million shares of Arrowhead Research Corporation exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $23.95-$26.88 after having opened the day at $24.06 as compared to the previous trading day's close of $21.14.

Arrowhead Research Corporation, a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. Arrowhead Research Corporation has a market cap of $796.9 million and is part of the drugs industry. Shares are up 85.1% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts who rate Arrowhead Research Corporation a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Arrowhead Research Corporation as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow. Get the full Arrowhead Research Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Novartis ( NVS) is up $0.68 (0.8%) to $83.25 on average volume. Thus far, 812,952 shares of Novartis exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $82.95-$83.39 after having opened the day at $83.19 as compared to the previous trading day's close of $82.57.

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. Novartis has a market cap of $197.2 billion and is part of the drugs industry. Shares are up 1.1% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts who rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.51 (1.0%) to $49.92 on average volume. Thus far, 2.6 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6.6 million shares. The stock has ranged in price between $49.28-$50.28 after having opened the day at $49.31 as compared to the previous trading day's close of $49.41.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $46.2 billion and is part of the drugs industry. Shares are up 21.7% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts who rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers